|
|
Article: Cephalon Receives FDA Approval of PROVIGIL(R) (modafinil) Tablets [C-IV], A Novel, Wakefulness-Promoting Treatment for Excessive Daytime Sleepiness Associated With Narcolepsy.
- Article from:
- PR Newswire
- Article date:
- December 28, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Cephalon's First U.S. Approval is Milestone for Company --
WEST CHESTER, Pa., Dec. 28 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market PROVIGIL(R) (modafinil) Tablets, a new, non- amphetamine drug to improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. PROVIGIL is a first-line treatment that is well-tolerated.
"PROVIGIL is a significant advance in sleep medicine and exemplifies Cephalon's commitment to addressing unmet medical needs with innovative therapies," said Frank Baldino, Jr., Ph.D., President ...